Key terms
About IMMP
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987, and is headquartered in Sydney, Australia.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IMMP news
Mar 07
12:00am ET
Analyst Issues Buy Rating on Immutep Stock Amid Promising Efti Drug Trial Results
Mar 05
8:08am ET
Immutep announces first clinical data from 90mg dosing of efti
Feb 01
12:35am ET
Buy Rating Affirmed for Immutep on Strong Clinical Pipeline and Market Potential
Jan 30
8:16am ET
Immutep reports Q2 cash receipts $38K vs. $132K last quarter
Jan 14
7:16am ET
Jefferies Keeps Their Buy Rating on Immutep Ltd (PRRUF)
Jan 07
7:33am ET
Immutep Ltd (PRRUF) Gets a Buy from Jefferies
Jan 04
8:30am ET
Immutep announces first patient enrolled, dosed in INSIGHT-005 trial
Jan 03
7:39am ET
Jefferies Sticks to Their Buy Rating for Immutep Ltd (PRRUF)
Dec 29
7:41am ET
Jefferies Reaffirms Their Buy Rating on Immutep Ltd (PRRUF)
Dec 26
7:38am ET
Jefferies Sticks to Their Buy Rating for Immutep Ltd (PRRUF)
Dec 24
7:51am ET
Jefferies Sticks to Their Buy Rating for Immutep Ltd (PRRUF)
Dec 21
8:08am ET
Immutep receives constructive feedback on TACTI-004 trial
Dec 07
8:11am ET
Immutep receives EUR 1.595M R&D tax incentive from French government
No recent news articles are available for IMMP
No recent press releases are available for IMMP
IMMP Financials
Key terms
Ad Feedback
IMMP Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IMMP Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range